Interestingly, in medulloblastoma BCL-2 is the least frequently expressed of the anti-apoptotic BCL-2 proteins [82, 83], although expression is associated with poorly differentiated and highly proliferative tumour regions, and tends to correlate with poor outcome [84]. This evidence concerns the gene BCL2 and medulloblastoma.